Coca-Cola beats earnings estimates, raises outlook as volume grows despite price hikes

Coca-Cola beats earnings estimates, raises outlook as volume grows despite price hikes


A Coca-Cola truck in New York City.

Alexi Rosenfeld | Getty Images

Coca-Cola on Tuesday reported quarterly earnings and revenue that topped analysts’ expectations and hiked its full-year outlook.

Shares of the company rose more than 2% in premarket trading.

Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Earnings per share: 74 cents adjusted vs. 69 cents expected
  • Revenue: $11.91 billion adjusted vs. $11.44 billion expected

Coke reported third-quarter net income attributable to shareholders of $3.09 billion, or 71 cents per share, up from $2.83 billion, or 65 cents per share, a year earlier.

Excluding transactions gains, restructuring costs and other items, the beverage giant earned 74 cents per share.

Net sales rose 8% to $11.91 billion, excluding items.

For the full year, Coke now expects comparable earnings per share growth of 7% to 8%, up from its prior range of 5% to 6%. The company also adjusted its outlook for organic revenue, forecasting an increase of 10% to 11%, up from the prior range of 8% to 9%.



Source

These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More
Wealthy donors stand to win double tax benefit if ‘Trump Accounts’ allow stock donations
Business

Wealthy donors stand to win double tax benefit if ‘Trump Accounts’ allow stock donations

President Donald Trump onstage at the Treasury Department’s Trump Accounts Summit, in Washington, Jan. 28, 2026. Kevin Lamarque | Reuters A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. With the Trump […]

Read More